Synthetic Immunotherapy Platform for Vaccine Development
Avalia Immunotherapies Limited, NA, New Zealand
Avalia Immunotherapies has developed a platform technology to deliver therapeutic cancer vaccines that activate the most powerful tumor-fighting cells in the body. The vaccines are discrete synthetic compounds that deliver both a cancer-specific peptide antigen and a powerful immune system activator simultaneously to dendritic cells.
Primary Application Area: Pharmaceuticals & Personal Care
Technology Development Status: Prototype
Technology Readiness Level: TRL 5
FIGURES OF MERIT
Value Proposition: Avalia’s technology has the potential to offer fully synthetic, therapeutic cancer vaccines that activate the most powerful tumor fighting cells in the body. The vaccines have a unique mechanism of action to immunotherapies in development and are also suitable for combination therapies, alongside traditional options, such as chemotherapy.
Organization Type: Early-stage Startup (Seed)
Showcase Booth #: 401
GOVT/EXTERNAL FUNDING SOURCES
Government Funding/Support to Date:
Primary Sources of Funding: Venture Capital, University
Looking for: Both Funding and Development Partners